Clinical trial NCT06120816: Nitric Oxide Releasing Mouthwash (NORM) for the Management of Oropharyngeal Candidiasis
Official title: Phase 1 Single Centre, Open-labeled Clinical Trial to Evaluate the Safety and Tolerability of Topical Nitric Oxide Releasing Mouthwash (NORM) for the Management of Oropharyngeal Candidiasis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Candidiasis, Oral
Keywords: oral candidiasis
Lead sponsor: Sanotize Research and Development corp.
Sponsor class: INDUSTRY
First posted: 2023-11-07
Enrollment: 6
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Open label
Primary purpose: TREATMENT

Brief summary: Phase 1 Single Centre, open-labeled Clinical Trial to Evaluate the Safety and Tolerability of Topical Nitric Oxide Releasing Mouthwash (NORM) for the Management of Oropharyngeal Candidiasis.

Participants that meet all inclusion and exclusion criteria will be enrolled to receive open label NORM 3 doses/day for three weeks.

Detailed description: This is a single-center, open-label phase 1 clinical trial to evaluate NORM safety, tolerance and ability to eliminate Candida sp from the oropharyngeal cavity.

Adult volunteer patients with dry mouth and confirmed presence of candida (by oral smear due to any cause will be eligible, including autoimmune disease, idiopathic (aging, tobacco, approved inhaled recreational drug, or alcohol use), and medical management including chemotherapy-induced, radiotherapy-induced, bone marrow transplantation-induced, medication use including antibiotics, anti-inflammatories, etc.

Sufficient participants will be enrolled to achieve 10 evaluable participants. Participants who are currently pursuing other forms of treatment (within 2 weeks prior to enrollment) will be excluded from the study (unless participant agrees to a two weeks wash out period).

Eligibility criteria: Inclusion Criteria:

1. At least 19 years old at the time of consent.
2. Participants must be diagnosed with clinical candidiasis.
3. Have no acute illnesses or hospitalizations within 30 days prior to enrollment, no planned procedures during the anticipated study participation, and no newly diagnosed chronic illnesses that are not deemed stable by the participant's primary care physician), in the opinion of the Investigator, based on medical history (i.e., absence of any clinically relevant abnormality) during Screening.
4. Participants must not have been part of any clinical trial for the past 30 days and may not be taking any other investigational therapy related to treatment of candidiasis.
5. If female, be surgically sterile or post-menopausal (no menses for at least 12 months), or if of childbearing potential, must be using an acceptable method of contraception such as a combination estrogen/progestin hormonal contraceptive (oral or injected) for at least 1 month prior to Day -14, or such items as an intrauterine device (IUD), intrauterine system (IUS), transdermal hormonal implant, vaginal hormonal ring, or 2 forms of the following: diaphragm, cervical cap, patch, condom, spermicide, or sponge. Total abstinence is permitted. If local regulations deviate from the previously listed contraception methods to prevent pregnancy, local requirements will apply. In addition, females of childbearing potential must agree to continue to use their method of birth control for the duration of the study.
6. If male, be surgically sterile, or agree to use appropriate contraception (latex condom with spermicide) when engaging in sexual activity and agree to not donate sperm for the duration of the study.
7. Be able to understand and provide written, informed consent.
8. Must be willing and able to manage a treatment regimen and attend assessment study visits.

Exclusion Criteria:

1. Participants with mucosal/oral ulceration
2. No prior antifungal therapies for a minimum 2-week prior to enrollment
3. Participants with other conditions considered by the investigator to be reasons for disqualification that may jeopardize patient safety or interfere with the objectives of the trial (e.g., acute illness or exacerbation of chronic illness, lack of motivation, history of poor compliance, neurologically or mentally disabled)
4. Females who are breastfeeding, pregnant, or attempting to become pregnant.
5. Participants with hypersensitivity to any of the product's ingredients.

Primary outcomes:
measure: To assess the tolerability of NORM in participants with candidiasis.
timeFrame: 21 days
Secondary outcomes:
measure: To assess the effectiveness of NORM to resolve oral fungal infection
timeFrame: 21 days
measure: To assess the effectiveness of NORM to resolve clinical symptoms of candidiasis
timeFrame: 21 days
measure: To assess the effectiveness of NORM to reduce the need for an oral antifungal agent
timeFrame: 21 days
Other outcomes:
measure: To categorize the major reasons impacting the tolerance of NORM during oral administration
timeFrame: 21 days
measure: Determine incidence and severity of adverse reactions
timeFrame: 21 days
measure: To assess reoccurrence of candidiasis
timeFrame: 28 days
measure: To assess of exacerbation of candidiasis
timeFrame: 28 days
Locations:
city: Vancouver
country: Canada
facility: Atlantis Dental Cambie
state: British Columbia
Study officials:
affiliation: SaNOtize R&D Corp
name: Keith Moore, PHARMMD
role: STUDY_DIRECTOR
affiliation: Atlantis Dental Cambie
name: Joel Epstein
role: PRINCIPAL_INVESTIGATOR
References: